Share on LinkedInShare on LinkedIn

ARTICLE · 20 AUGUST 2025

Market Intelligence Thought Leadership Award Winner

Antitrust Life Sciences Quarterly Update 2025 Q2

The first half of 2025 has seen an acceleration of M&A activity, including large-scale life sciences transactions, such as Merck's $3.9 billion acquisition of SpringWorks...

GlobalAntitrust/Competition Law

The first half of 2025 has seen an acceleration of M&A activity, including large-scale life sciences transactions, such as Merck's $3.9 billion acquisition of SpringWorks, Sanofi's $9.5 billion acquisition of Blueprint Medicines, and Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies, as well as notable developments in litigation and enforcement by European and UK regulators. As discussed in this update, these outcomes can provide important guidance for life sciences companies as they structure their transactional and regulatory activity.

Pomalyst Decision Holds Most-Favored-Entry Clause Survives Antitrust Scrutiny, Charting Clearer Path for Structuring Pharma Settlements

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from